MedTrace Logo

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2018-03-12

No results posted yet for this study

Summary

The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBIâ„¢ Podhalerâ„¢ and continuous alternating therapy with TOBIâ„¢ Podhaler and colistimethate (Colistin).

Conditions

Interventions

DRUG

TOBIâ„¢ Podhalerâ„¢ 112 mg inhaled twice daily

DRUG

Colistimethate 75 mg inhaled two times daily

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-08-31
Completion
2016-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02113397 on ClinicalTrials.gov